12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Array BioPharma, Loxo deal

Array granted newco Loxo exclusive, worldwide rights to develop and commercialize undisclosed cancer candidates and related IP targeting an undisclosed oncogenic activating mutation. Loxo will fund preclinical research conducted by Array over a three-year research phase,...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >